BonAlive®
BonAlive® is a bone graft substitute for Augmentation or Reconstruction of the Cranio-Maxillofacial Skeleton. It is osteoconductive, bioactive, and inhibits bacterial growth.
BonAlive® has provided successful long-term clinical outcomes for over a decade in cranio-maxillofacial surgery.1,3
The composition of BonAlive® (S53P4) by weight is:
- SiO2 53%
- Na2O 23%
- CaO 20%
- P2O5 4%
Features
BonAlive® Inhibits Bacterial Growth
BonAlive® is a bone graft substitute that inhibits bacterial growth. Studies have shown that the material has a bacterial growth inhibiting effect on a vast number of anaerobic and aerobic bacterial species that are related to cranio-maxillofacial complications5,6,8,9.
Indications
BonAlive® granules is intended for the augmentation or reconstruction of the cranio-maxillofacial skeleton.
BonAlive® in Mastoid Obliteration
BonAlive® in Frontal Sinus Obliteration
Warnings and Precautions
Warnings and Precautions
BonAlive® granules is only intended for use by medically qualified professionals and the user must be familiar with bone grafting and fixation techniques.
BonAlive® granules does not provide mechanical strength to support load-bearing defects before hard tissue has formed. If a fracture requires load supporting fixation, standard internal or external stabilization techniques must be used to achieve rigid stabilization in all planes. Screw purchase or screw stabilization must not be attempted on recent BonAlive® granules implantation sites, where sufficient bone growth is not observed.
BonAlive® granules is not intended for use with defects other than those listed in the indication statement. The device has not been clinically tested for use in pregnant women.
References
References
- Bioactive glass S53P4 in frontal sinus obliteration: a long-term clinical experience. Peltola M., Aitasalo K., Suonpää J., Varpula M., Yli-Urpo A. Head&Neck, 2006, Vol. 28:834-841.
- Bioactive glass hydroxyapatite in fronto-orbital defect reconstruction. Aitasalo K., Peltola M. Plast Reconstr Surg, 2007, Dec; 120(7):1963-72.
- Bioactive glass S53P4 in the filling of cavities in the mastoid cell area in surgery for chronic otitis media. Stoor P., Pulkkinen J., Grénman R. Annal Otol Rhinol Laryngol. 2010 Jun; 119(6):377-82.
- Molecular basis for action of bioactive glasses as bone graft substitute. Välimäki V-V., Aro H., Scand J Surg 2006; 95(2):95-102.
- Bactericidal effects of bioactive glasses on clinically important aerobic bacteria. Munukka E., Leppäranta O., Korkeamäki M., Vaahtio M., Peltola T., Zhang D., Hupa L., Ylänen H., Salonen J., Viljanen M., Eerola E. J Mat Sci: Materials in Medicine, 2008, Jan: 19(1):27-32.
- Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro. Leppäranta O., Vaahtio M., Peltola T., Zhang D., Hupa L., Hupa M., Ylänen H., Salonen J., Viljanen M., Eerola E. J Mat Sci, Materials in Medicine, 2008 Feb; 19(2):547-551.
- Histomorphometric and molecular biologic comparison of bioactive glass granules and autogenous bone grafts in augmentation of bone defect healing. Virolainen P., Heikkilä J., Yli-Urpo A, Vuorio E, Aro HT. J Biomed Mat Res Part A, 1997, 35(1):9-17.
- Interactions between the frontal sinusitis-associated pathogen Haemophilus Influenzae and the bioactive glass S53P4. Stoor P., Söderling E., Grenman R. Bioceramics, 1995, Vol. 8:253-258.
- Interactions between the bioactive glass S53P4 and the atrophic rhinitis-associated micro-organism Klebsiella ozaenae. Stoor P., Söderling E., Grenman R. J Biomed Mat Res (Appl Biomat), 1999, Vol. 48(6):869-874.